Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare condition where the immune system mistakenly attacks protective covering around nerves. While there is no cure for MOGAD, modern medicine offers several approaches to help patients recover from attacks, manage symptoms, and prevent future episodes. Treatment approaches range from established therapies approved for use to experimental methods currently being evaluated in clinical research settings.

How Medicine Approaches MOGAD: Goals and Treatment Paths

When someone receives a diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease, the main goal of treatment is to help them recover from active attacks and prevent future episodes that could cause lasting damage. The immune system in people with MOGAD produces antibodies that attack a protein called MOG, which sits on the outer surface of myelin—the fatty substance that insulates nerve fibers in the brain, spinal cord, and optic nerves. When this protective covering is damaged, the messages traveling through nerves can be slowed or blocked, leading to symptoms like vision loss, muscle weakness, confusion, and problems with coordination.^[1]

Treatment decisions depend heavily on whether a person has experienced just one attack or multiple episodes. Some people with MOGAD have what doctors call monophasic disease, meaning they experience only one attack of symptoms in their lifetime. Others have relapsing disease, where symptoms go away for a period of time before coming back again. This distinction matters because it guides how aggressively doctors treat the condition and whether long-term preventive therapy is needed.^[2]

The disease affects children and adults somewhat differently. In children, MOGAD most commonly targets the brain, causing a condition called acute disseminated encephalomyelitis (ADEM), which brings symptoms like confusion and loss of coordination. In adults, the disease more often affects the spinal cord and eyes, causing weakness, numbness, and blurry vision. These differences influence treatment choices and expectations for recovery.^[3]

Standard Treatment Approaches for MOGAD

Treating Active Attacks

When someone experiences an active MOGAD attack, the immediate priority is to stop the immune system from causing further damage and help the person recover as much function as possible. The most common first-line treatment involves high doses of corticosteroids, which are powerful anti-inflammatory medications. These are typically given through a vein in the arm (intravenously) over several days. The most commonly used steroid is methylprednisolone, usually administered at high doses for three to five days.^[4]

After the initial intravenous steroid treatment, patients typically continue taking steroids by mouth in gradually decreasing doses over several weeks or months. This tapering approach helps prevent the attack from returning while giving the body time to stabilize. The duration of this oral steroid treatment varies depending on how severe the attack was and how well the person is recovering. Some people may need to take oral steroids for several months.^[9]

If high-dose steroids don’t lead to adequate improvement, or if the attack is particularly severe, doctors may turn to plasma exchange (also called plasmapheresis). This procedure involves removing blood from the body, filtering out the harmful antibodies, and returning the cleaned blood. The process typically requires five to seven sessions performed over one to two weeks. Plasma exchange can be especially helpful when started early in severe attacks that affect vision or cause significant paralysis.^[4]

Another option for acute treatment is intravenous immunoglobulin (IVIG), which involves infusing antibodies collected from healthy donors into the patient’s bloodstream. These donated antibodies can help regulate the immune system and reduce inflammation. IVIG is often used when steroids haven’t worked well or when there are reasons why steroids or plasma exchange might not be suitable for a particular patient.^[9]

Preventing Future Attacks

Not everyone with MOGAD needs long-term preventive treatment. Because about 40 to 50 percent of people experience only one attack in their lifetime, doctors typically reserve ongoing preventive therapy for those who have had multiple attacks or who had a particularly severe first attack that caused lasting disability such as blindness or paralysis.^[13]

For people with relapsing MOGAD, several medications can help suppress the immune system and reduce the likelihood of future attacks. There are currently no medications specifically approved by the U.S. Food and Drug Administration for MOGAD, so doctors prescribe these treatments “off-label,” meaning they use medications approved for other conditions but that have shown benefit for MOGAD based on clinical experience.^[13]

One commonly used preventive medication is mycophenolate mofetil (brand name CellCept), which works by suppressing certain types of immune cells. Patients typically take this medication as pills twice daily. Another option is rituximab (brand name Rituxan), which targets and removes a specific type of immune cell called B cells. This medication is given through intravenous infusions, typically every six months.^[13]

Azathioprine (brand name Imuran) is another immunosuppressive medication that can be used to prevent MOGAD attacks. It’s taken daily as a pill. Some people also receive regular infusions or subcutaneous injections of immunoglobulin (IVIG or SCIG) as a preventive strategy. The subcutaneous form involves injecting immunoglobulin under the skin, which patients can learn to do at home, making treatment more convenient.^[8]

Side Effects and Monitoring

All immunosuppressive medications carry risks because they weaken the body’s ability to fight infections. People taking these medications are more likely to develop upper respiratory infections, urinary tract infections, and other illnesses. Regular blood tests are necessary to monitor blood cell counts and liver and kidney function. Doctors carefully weigh these risks against the benefits of preventing potentially disabling MOGAD attacks.^[13]

Corticosteroids, especially when used for extended periods, can cause additional side effects including weight gain, mood changes, increased blood sugar, bone thinning, and increased risk of infections. These effects are why doctors try to taper steroids as quickly as safely possible after an acute attack.^[9]

Treatment Approaches Being Studied in Clinical Trials

Because MOGAD is a relatively recently recognized disease and current treatments are not specifically designed for it, researchers are actively investigating new therapeutic approaches through clinical trials. These studies are exploring whether medications developed for similar conditions might work better for MOGAD, as well as entirely new treatment strategies.

Complement Inhibitors

One promising area of research involves medications that block part of the immune system called the complement system. In MOGAD, when antibodies attach to MOG protein on myelin, they activate this complement system, which contributes to inflammation and damage. Studies have found deposits of complement proteins in the brain and spinal cord lesions of people with MOGAD, suggesting that blocking this pathway might reduce damage.^[4]

Complement inhibitors work by preventing the complement system from completing its attack on tissues. While these medications have been studied more extensively in a related condition called neuromyelitis optica spectrum disorder, researchers are now evaluating whether they might also benefit people with MOGAD. The biological mechanisms of tissue damage appear to overlap between these conditions, making complement inhibitors a logical treatment target to investigate.^[4]

B Cell Targeting Therapies

Because B cells are the immune cells responsible for producing the harmful MOG antibodies, several clinical trials are examining medications that specifically target these cells. Rituximab, already used off-label for MOGAD prevention, is being studied more systematically in trials to better understand its effectiveness and optimal dosing schedule.^[16]

Newer B cell-targeting medications are also being explored. These include agents that work through different mechanisms than rituximab but achieve the same goal of reducing or eliminating the B cells that produce MOG antibodies. Some of these medications may offer advantages such as longer-lasting effects or fewer side effects, though this research is still in early stages.^[16]

IL-6 Receptor Blockers

Another promising approach involves blocking a molecule called interleukin-6 (IL-6), which plays an important role in inflammation. Medications that block the receptor for IL-6 prevent this inflammatory signaling. This approach has shown benefit in neuromyelitis optica, and researchers are now investigating whether it might also help prevent attacks in people with MOGAD. These medications are typically given as injections under the skin every few weeks.^[11]

Understanding Clinical Trial Phases

Clinical trials for MOGAD treatments typically progress through several phases. Phase I trials focus primarily on safety, involving small numbers of participants to determine whether a medication is safe enough to study further. Phase II trials involve more people and begin to assess whether the treatment actually works—for example, whether it reduces the frequency of attacks or improves recovery. Phase III trials are large studies that compare the new treatment against either a placebo or current standard treatments to definitively prove effectiveness.^[16]

Many clinical trials for MOGAD are being conducted at specialized medical centers in the United States, Europe, and other regions around the world. People interested in participating typically need to meet specific criteria, such as having had a certain number of attacks within a specific timeframe or testing positive for MOG antibodies at a particular level. Trial coordinators work closely with potential participants to determine eligibility.^[16]

Innovative Approaches Under Investigation

Beyond medications that broadly suppress the immune system, researchers are exploring more targeted approaches. Some studies are investigating whether it’s possible to “retrain” the immune system so it stops attacking MOG while still maintaining the ability to fight infections. This approach, called immune tolerance therapy, represents a potential future direction for MOGAD treatment, though it remains experimental.^[11]

Other researchers are studying biomarkers—measurable substances in blood or spinal fluid that might predict who will have relapses, who will respond best to which treatments, or when attacks are likely to occur. Having better biomarkers could help doctors personalize treatment choices for each individual patient. Studies have found that people who continue to test positive for MOG antibodies may have a higher chance of experiencing additional attacks, making antibody levels a potentially useful monitoring tool.^[13]

Most common treatment methods

• High-dose corticosteroids
  • Intravenous methylprednisolone given over three to five days to stop active attacks
  • Followed by oral steroids taken in gradually decreasing doses over weeks or months
  • First-line treatment for acute MOGAD attacks
• Plasma exchange (plasmapheresis)
  • Removes harmful antibodies from the blood through five to seven sessions
  • Used when steroids don’t provide adequate improvement
  • Particularly helpful in severe attacks affecting vision or causing paralysis
• Immunoglobulin therapy
  • Intravenous immunoglobulin (IVIG) infusions during acute attacks
  • Subcutaneous immunoglobulin (SCIG) injections for long-term prevention
  • Can be administered at home for convenience
• Immunosuppressive medications
  • Mycophenolate mofetil (CellCept) taken as pills twice daily
  • Rituximab (Rituxan) given as intravenous infusions every six months
  • Azathioprine (Imuran) taken daily as pills
  • Used to prevent attacks in people with relapsing MOGAD
• Complement inhibitors (experimental)
  • Block the complement system that contributes to inflammation and damage
  • Currently being studied in clinical trials
  • Show promise based on findings in related neurological conditions
• B cell targeting therapies (experimental)
  • Target the immune cells that produce MOG antibodies
  • Include both established medications like rituximab being studied more systematically
  • Newer agents with potentially improved effectiveness or fewer side effects
• IL-6 receptor blockers (experimental)
  • Prevent inflammatory signaling by blocking interleukin-6
  • Given as injections under the skin every few weeks
  • Being investigated based on success in similar conditions